SHU9119: the MC4R antagonist that revealed the melanocortin appetite brake

The brake made visible - block the melanocortin signal and a body reaches for food, proof that the system's quiet work is restraint.

Most of the molecules on this site were built to switch a melanocortin receptoron. SHU9119 is the reference tool for doing the opposite. It is the best-characterised melanocortin MC4R antagonist, a laboratory peptide that, more than any drug, taught the field what the melanocortin system is actually for - and it did so by blocking it and watching what broke.^[2]

An agonist turned inside out

SHU9119 has a striking pedigree: it comes from the same University of Arizona melanotropin programme, and largely the same chemists, as the tanning peptide Melanotan II. The two molecules are close cousins. Take the cyclic MT-II scaffold and swap the residue at position 7 - the D-phenylalanine that sits at the heart of the melanocortin message - for a bulkier aromatic amino acid, a D-2-naphthylalanine, and the molecule stops activating the appetite and pigment-appetite receptors and starts blocking them instead.^[1] One deliberate substitution converts a broad agonist into a potent, selective antagonist. It is the clearest illustration on the site that agonist and antagonist are not different worlds but neighbours on one chemical street.

The receptor profile is unusual and useful. SHU9119 is a potent antagonist at MC4R and MC3R, a partial agonist at MC5R, and - the twist - a full agonist at MC1R, the pigment receptor.^[1] That it can gag the appetite receptor while still speaking to the pigment receptor is exactly what makes it a scalpel for separating the melanocortin system's jobs.

The experiment that proved the brake

SHU9119's fame rests on a single, elegant 1997 study. Researchers already suspected the melanocortin system restrained appetite, but suspicion is not proof. So they blocked it. Injected directly into the brain, SHU9119 did two things: it abolished the appetite-suppressing effect of the melanocortin agonist MT-II across several models of overeating, and, given on its own, it increased feeding, deepening the hunger of fasted or night-feeding animals.^[2]

The conclusion reframed the whole system. Melanocortin neurons are not an occasional "stop eating" signal; they exert a constant, tonic brake on feeding, and lifting that brake drives overeating. The same paper closed a long-standing puzzle: the agouti obesity syndrome, in which mice grow fat because they ectopically express a natural melanocortin blocker, is what chronic MC4R antagonism looks like. SHU9119 was, in effect, a synthetic stand-in for that natural blocker - which is why the body's own version, the hunger peptide AgRP, does the same job on the same receptor.^[2]

A tool, not a therapy

It is worth being blunt about what SHU9119 is: a research reagent. Blocking MC4R chronically does not treat anything - it causes the problem, driving overeating, weight gain, and metabolic disturbance in animals, a deliberate model of obesity rather than a cure for it.^[2] That is the opposite of a weight-loss drug, and SHU9119 has never been a candidate medicine. The therapeutic version of the same idea, engineered to be safe, brain-penetrant, and pointed at wasting rather than obesity, is TCMCB07 (mifomelatide) - an MC4R antagonist built as a therapy for cachexia. SHU9119 is the tool that proved the target; TCMCB07 is one attempt to drug it.

The ligand in the landmark structure

SHU9119 has a second, quieter claim to importance. When the structure of the human MC4R was finally solved in 2020, SHU9119 was the ligand bound inside it. That structure did more than show the receptor's shape: it revealed a calcium ion sitting in the binding pocket, complexed with both the receptor and the peptide - a cofactor that sharply increases the affinity and potency of the natural agonist α-MSH.^[3] Much of what the MC4R page describes about how the appetite receptor really works was read off a crystal with SHU9119 locked in place. For where its blocking strength sits against the agonists and the other natural brake, see the binding matrix.

Common questions

What is SHU9119?+

SHU9119 is a synthetic cyclic peptide and the classic melanocortin antagonist. It blocks the MC3 and MC4 receptors (and is a partial agonist at MC5R), while acting as an agonist at MC1R. It is a laboratory research tool, not a medicine, and it is best known for the experiment that proved melanocortin signalling is the brain’s brake on hunger.

Is SHU9119 an agonist or an antagonist?+

Both, depending on the receptor. At MC3R and MC4R it is an antagonist that blocks the receptor; at MC5R it is a partial agonist; and at MC1R it is a full agonist. That split is why it is such a useful tool: it can silence the appetite receptor while leaving the pigment receptor switched on.

How is SHU9119 different from TCMCB07?+

Both block MC4R, but they were built for opposite purposes. SHU9119 is a research reagent, and chronically blocking MC4R with it makes animals overeat and gain weight, phenocopying the agouti obesity syndrome. TCMCB07 (mifomelatide) is a drug candidate that uses the same MC4R blockade deliberately, to lift appetite and preserve body weight in cachexia. One is a lab tool that induces obesity; the other is a therapy for wasting.

Why does SHU9119 matter?+

Two reasons. First, the 1997 experiment: injected into the brain it made animals eat and blocked the appetite-suppressing effect of a melanocortin agonist, proving that melanocortin neurons tonically restrain feeding and explaining the agouti obesity syndrome. Second, it is the ligand in the 2020 crystal structure of MC4R that revealed calcium as a cofactor for melanocortin binding.

References

1. 1.Hruby VJ, Lu D, Sharma SD, Castrucci AL, Kesterson RA, al-Obeidi FA, Hadley ME, Cone RD. Cyclic lactam α-melanotropin analogues with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J Med Chem. 38(18):3454–61. 1995. link ↗
2. 2.Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 385(6612):165–8. 1997. link ↗
3. 3.Yu J, Gimenez LE, Hernandez CC, et al. Determination of the melanocortin-4 receptor structure identifies Ca²⁺ as a cofactor for ligand binding. Science. 368(6489):428–33. 2020. link ↗